Skip to main content

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Publication ,  Journal Article
Gotlib, J; Gerds, AT; Bose, P; Castells, MC; Deininger, MW; Gojo, I; Gundabolu, K; Hobbs, G; Jamieson, C; McMahon, B; Mohan, SR; Oehler, V ...
Published in: J Natl Compr Canc Netw
December 2018

Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocytosis diagnosed in adults, characterized by mast cell infiltration of one or more extracutaneous organs (with or without skin involvement). The identification of KIT D816V mutation and the emergence of novel targeted therapies have significantly improved the diagnosis and treatment of systemic mastocytosis. However, certain aspects of clinical care, particularly the diagnosis, assessment, and management of mediator-related symptoms continue to present challenges. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with systemic mastocytosis.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

December 2018

Volume

16

Issue

12

Start / End Page

1500 / 1537

Location

United States

Related Subject Headings

  • mRNA Cleavage and Polyadenylation Factors
  • Treatment Outcome
  • Transplantation, Homologous
  • Societies, Medical
  • Receptor, Platelet-Derived Growth Factor alpha
  • Proto-Oncogene Proteins c-kit
  • Patient Care Team
  • Oncology & Carcinogenesis
  • Oncogene Proteins, Fusion
  • Mutation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gotlib, J., Gerds, A. T., Bose, P., Castells, M. C., Deininger, M. W., Gojo, I., … Sundar, H. (2018). Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 16(12), 1500–1537. https://doi.org/10.6004/jnccn.2018.0088
Gotlib, Jason, Aaron T. Gerds, Prithviraj Bose, Mariana C. Castells, Michael W. Deininger, Ivana Gojo, Krishna Gundabolu, et al. “Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw 16, no. 12 (December 2018): 1500–1537. https://doi.org/10.6004/jnccn.2018.0088.
Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, et al. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Dec;16(12):1500–37.
Gotlib, Jason, et al. “Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw, vol. 16, no. 12, Dec. 2018, pp. 1500–37. Pubmed, doi:10.6004/jnccn.2018.0088.
Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Dec;16(12):1500–1537.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

December 2018

Volume

16

Issue

12

Start / End Page

1500 / 1537

Location

United States

Related Subject Headings

  • mRNA Cleavage and Polyadenylation Factors
  • Treatment Outcome
  • Transplantation, Homologous
  • Societies, Medical
  • Receptor, Platelet-Derived Growth Factor alpha
  • Proto-Oncogene Proteins c-kit
  • Patient Care Team
  • Oncology & Carcinogenesis
  • Oncogene Proteins, Fusion
  • Mutation